Fig. 6
Expression Analysis of BEX1 in Glioma Tissue Samples. (A-F) Western blot analysis confirming significantly reduced BEX1 protein levels in tumor tissues compared to adjacent non-tumor tissues from 12 glioma patients. (G-I) qRT-PCR analysis validating significantly decreased BEX1 mRNA levels in tumor tissues relative to adjacent non-tumor samples across all cases. (J) Representative immunofluorescence images of WHO grade II and IV glioma tissues stained for p-AKT, p-ERK, p-STAT3, CDK1, BEX1, and DAPI. (K) Quantification of relative fluorescence intensity showing increased p-AKT, p-ERK, p-STAT3, and CDK1, and decreased BEX1 in WHO grade IV gliomas (n = 3). (L) Co-immunoprecipitation in LN229 and U251 cells co-transfected with Flag-BEX1 and His-AKT. BEX1 physically associates with AKT, as shown by reciprocal IP with anti-Flag and anti-His antibodies. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01; ns: not significant.
